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Abstract Vaccines are one of the most successful public
health achievements of the last century. Systematic im-
munisation programs have reduced the burden of infectious
diseases on a global scale. However, there are limitations to
the current technology, which often requires costly infra-
structure and long lead times for production. Furthermore,
the requirement to keep vaccines within the cold-chain
throughout manufacture, transport and storage is often
impractical and prohibitively expensive in developing
countries—the very regions where vaccines are most nee-
ded. In contrast, plant-made vaccines (PMVs) can be pro-
duced at a lower cost using basic greenhouse agricultural
methods, and do not need to be kept within such narrow
temperature ranges. This increases the feasibility of
developing countries producing vaccines locally at a small-
scale to target the speciﬁc needs of the region. Addition-
ally, the ability of plant-production technologies to rapidly
produce large quantities of strain-speciﬁc vaccine demon-
strates their potential use in combating pandemics. PMVs
are a proven technology that has the potential to play an
important role in increasing global health, both in the
context of the 2015 Millennium Development Goals and
beyond.
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Introduction
At the 2000 UN Millennium Summit, world leaders com-
mitted to addressing the Millennium Development Goals,
aimed at improving social and economic conditions in
developing countries. The eight goals cover various issues
associated with poverty, education, health and sustainable
development. Plant-made vaccines (PMVs) have the ability
to directly address the health-related goals, speciﬁcally the
targeted reductions in incidence of major diseases, and of
child mortality due to preventable diseases such as cholera
and enterotoxigenic Escherichia coli.
Plant molecular biology and biotechnology have
enhanced and expanded the medicinal applications of plants
in many ways. Plants can be engineered to act as bioreactors
for vaccine and therapeutic production, and their metabolic
pathways can be manipulated to increase compounds of
beneﬁt or decrease detrimental compounds. While some of
these activities can be achieved through mutagenesis and
traditional plant breeding, the most direct and exacting path
is through genetic modiﬁcation or transformation of plant
cells. Expressing recombinant proteins in transgenic plants
has been actively researched for the past 20 years, resulting
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tools and techniques have been steadily building, and have
now reached the point where commercial production of
biopharmaceuticals by transgenic plants is a certainty.
Plants as protein production systems
Methods of transgene expression
The ability of transgenic plants to produce complex pro-
teins using low-grade technology makes them a powerful
tool for recombinant protein production. Proteins can be
produced through either stable or transient expression of
transgenes. Stable production systems involve the insertion
of a foreign gene into the genome of a host plant resulting
in the maintenance of the foreign gene in the host’s genetic
lineage over multiple generations. In contrast, transient
systems use bacterial or viral vectors to insert transgenes
into a host cell. The foreign gene or transgene is then
expressed for a relatively brief timespan. Until recently,
PMVs were plagued by concerns regarding low antigen
yields, regulatory issues around transgene containment, and
the potential for gene silencing to dramatically reduce
antigen yield. While this has slowed the commercial
development of the technology, much progress has been
made through various avenues of research. Recombinant
protein yields have been greatly increased in stable systems
though subcellular targeting and chloroplast transforma-
tion, with levels of up to 46% of total soluble protein (TSP)
being reported (Sharma and Sharma 2009). It has been
estimated that through the use of chloroplast genetic
engineering, 1 acre of tobacco expressing a protective
antigen from anthrax could produce up to 360 million
doses of anthrax vaccine (Koya et al. 2005). This approach
has the beneﬁts of negating gene silencing as it rarely
occurs in chloroplasts, and also provides a mechanism for
gene containment, as chloroplasts are maternally inherited
(Ruf et al. 2007).
Another commonly used method to increase protein
accumulation and avoid gene silencing is through the use
of transient expression (Kapila et al. 1997; Komarova et al.
2010). A recently described transient expression system,
‘magnifection’ (Gleba et al. 2005; Marillonnet et al. 2005),
has been demonstrated to rapidly produce clinically rele-
vant levels of a personalised therapeutic vaccine against
non-Hodgkin’s lymphoma in Nicotiana benthamiana
(Bendandi et al. 2010). This system has been shown to
result in a recombinant protein yield of up to 80% TSP
(Marillonnet et al. 2004), and it has been predicted that this
could result in vaccines produced for less than 0.01 USD
per 0.1 mg dose (Gleba et al. 2005). There are several
transient expression systems based on deconstructed
viruses, and it is not uncommon for yields to approach
or better 1 g/kg (Komarova et al. 2010). However, viral
systems suffer from several drawbacks, including size
restrictions on the gene being expressed, issues of bio-
containment, and difﬁculties associated with expressing
more than one protein at a time. In order to overcome these
hurdles, another system has been designed, based on a
disabled version of Cowpea mosaic virus RNA-2. This has
resulted in levels of foreign protein accumulation up to
20% TSP (Sainsbury and Lomonossoff 2008).
Puriﬁcation
The major cost of producing puriﬁed proteins such as
subunit vaccines is contained in the separation and puriﬁ-
cation steps, which can account for up to 90% of total
production costs (Cunha and Aires-Barros 2002). A beneﬁt
of plant-based expression systems is that they allow for
alternative puriﬁcation methods, such as elastin-like poly-
peptide (ELP) fusion technology. ELPs exhibit the unique
characteristic of reversible phase transition, meaning they
can be precipitated out of solution and re-suspended again
through temperature manipulation. The addition of ELPs to
a protein of interest allows it to be collected and separated
from host proteins via centrifugation of crude extracts
(Floss et al. 2010). Other puriﬁcation methods include the
use of hydrophobin tags to produce protein bodies within
the plant tissue, and oleosin tags to produce oil bodies.
These can be separated to varying purities from crude
protein extracts based on their density (Capuano et al.
2007; Joensuu et al. 2010).
Progress to market
To date, no PMV has made it onto the market. With no
clear precedent, there have been concerns regarding the
commercial feasibility of the technology. However, in
recent years multiple companies have progressed through
to Phase II and III trials (Faye and Gomord 2010), forcing
regulatory agencies to become involved. For example,
ORF Genetics produces several growth factors in stably
transformed barley for use in the cosmetic industry (ORF
Genetics 2010). Protalix BioTherapeutics has just com-
pleted a Phase III trial for taliglucerase alfa produced in
stable carrot cell cultures. Used to treat Gaucher disease,
the product was approved by the U.S Food and Drug
Administration (FDA), who have since accepted a New
Drug Application and granted a Prescription Drug User Fee
Act action date in early 2011 (Protalix BioTherapeutics
2010). SemBioSys have completed Phase II trials of insulin
produced in transgenic safﬂower, and have ﬁled an Inves-
tigational New Drug Application with the FDA, and sub-
mitted a Clinical Trial Application to European authorities
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Phase II trials for their avian inﬂuenza vaccine produced
transiently in tobacco, after receiving clearance from
Health Canada (Medicago 2010). It must be noted that all
the above examples are puriﬁed proteins, and with no set
precedent the path for unpuriﬁed PMVs remains unclear.
The need for thermo-stable vaccines
Current requirement for the vaccine cold-chain
Every year, millions of children die from vaccine-pre-
ventable diseases. While vaccines are one of the greatest
success stories in modern medicine, and one of the most
cost-effective public health measures available, more can
be done to allow vaccines to reach their full potential
(Frieden and Henning 2009). Due to time and distance
barriers between the point of manufacture and points of
use, uncertainty often arises as to whether the vaccine in
question has been maintained under conditions that pre-
serve effectiveness. This problem is compounded by the
fact that there is no easy and inexpensive test to settle this
uncertainty. As such, one greatly desired trait is the ability
to easily test vaccine potency, or better yet, for the vaccine
to be able to withstand wide temperature ranges before any
potency is lost. Many vaccines are sensitive to heat and
freezing, and as a result are often damaged though poor
temperature maintenance (Atkinson et al. 2002; Wirkas
et al. 2007). The temperature limitations of vaccines are
currently minimised through the use of the cold-chain, a
process in which products are kept within a deﬁned, often
refrigerated, temperature range from manufacture through
to distribution and storage (Weir and Hatch 2004). The
system is far from ideal, as the cost of maintaining the
cold-chain has been estimated at between 200 and 300
million USD annually (Das 2004), and there is little
guarantee that the chain will not be broken (Berhane and
Demissie 2000). As well as issues regarding practicality,
the affordability of a vaccine is a primary determinate of its
sustainable use in developing countries. The use of thermo-
stable vaccines would eliminate the need for the costly
cold-chain process, increase conﬁdence in vaccine efﬁcacy,
and release funds that would enable the vaccination of
more individuals.
Thermo-stability of PMVs
Plant-based production systems offer a platform for the
manufacture of heat-stable recombinant proteins (Sto ¨ger
et al. 2000). This can be achieved by expressing the vac-
cine antigen in a plant storage body such as the seed or
tuber or within plant vegetative tissues or fruits. Harvested
material is processed through freeze-drying, crushing or
powdering, and pooled to produce a thermo-stable vaccine
batch that can be conveniently transported and stored at
ambient temperatures (Zhang et al. 2006). The plant seed
has emerged as one of the preferred plant storage organs
for vaccine antigen accumulation, with the current leading
platforms being rice and maize (Lau and Sun 2009). Unlike
in vegetative plant tissue, seed storage proteins are
sequestered within protein bodies, specialised vacuoles in
the mature seed that have low protease levels (Mu ¨ntz
1998). Recombinant proteins have been demonstrated to
accumulate at high levels in seeds, and have been dem-
onstrated to remain stable and immunogenic in both ani-
mals and humans for over 18 months when stored without
refrigeration (Chikwamba et al. 2002; Lamphear et al.
2002; Nochi et al. 2007).
Cholera is a major killer in developing countries, and the
recent outbreak during the Pakistan ﬂoods resulted in an
estimated 300,000 cases of acute diarrhoea (Enserink
2010). Freeze-drying tomatoes expressing subunit B from
the heat-labile enterotoxin secreted by enterotoxigenic
E. coli (LTB) has been shown to result in LTB fusion
proteins that are stable at room temperature for over 5
months (Walmsley et al. 2003). LTB has been proposed as
a vaccine candidate for cholera, as it is very similar in
structuretothecholeraantigenCTB,andthereisahigh-level
of immunological cross-reactivity between these proteins
(Svennerholm et al. 1986). Oral immunisation with pow-
dered transgenic rice expressing CTB (MucoRice-CTB)
has been shown to prevent diarrhoea in mice following
challenge with Vibrio cholerae and enterotoxigenic E. coli
(Tokuhara et al. 2010). Importantly, rice that had been
stored for over 3 years at ambient temperature was dem-
onstrated to induce neutralising antibodies at a level
comparable to freshly harvested material. The ability of
this vaccine to be stored without refrigeration in develop-
ing countries that suffer from regular cholera outbreaks is
of huge beneﬁt. As evidenced by recent events in Haiti,
pandemic outbreaks of diseases such as cholera are often
triggered by natural disasters, and are therefore often
associated with electricity shortages disrupting the cold-
chain. The thermo-stability of PMVs offer a deﬁnite gain
over the current cholera vaccine leader (Dukoral, SBL
Vaccines, Sweden), which has a shelf life of 3 years only
when stored at 2–8C (Galazka et al. 2006).
The ability to store and stockpile vaccines is crucial in
preparation for pandemics, as it allows for vaccination
campaigns to be undertaken at an early stage, mitigating
the impact of the disease. Yersinia pestis, the cause of
pneumonic, septicemic, and bubonic plague, is estimated to
cause between 1000 and 5000 cases per year (Stenseth
et al. 2008). Recent outbreaks include India in 1994 and the
Democratic Republic of the Congo in 2006. It is unlikely to
Plant Cell Rep (2011) 30:789–798 791
123ever be completely eliminated, as it is widespread in the
wildlife, with rodents acting as reservoirs (Gratz 1999).
While there is a vaccine available, it confers limited pro-
tection from the pneumonic form, requires multiple
boosters, and is associated with various side effects
(Bramwell et al. 2005). To address this issue, an orally
delivered booster vaccine consisting of a F1-V fusion
protein was expressed in tomatoes (Alvarez et al. 2006).
The fruits were freeze-dried, powdered and pooled, and
after being stored at room temperature immunogenicity
was conﬁrmed in mice. In another study, the F1-V fusion
was expressed in lettuce. This was found to be stable in
freeze-dried material for up to 6 months at 25C, and was
immunogenic when used as a sub-cutaneous primer and
oral booster (Rosales-Mendoza et al. 2010).
When stored at 2–8C as a freeze-dried powder, the
current live, attenuated measles vaccine is stable for up to
2 years (Galazka et al. 2006). However, when stored at
20–25C for 6 months, only one-third of vaccine activity
remains, and when stored at 36–38C, a similar decrease is
seen in just 3 weeks. When exposed to temperatures of
54–56C, this drop takes only 12 h (Galazka et al. 2006;
McAleer et al. 1980). A subunit measles PMV consisting of
the measles virus hemagglutinin protein expressed in let-
tuce was found to be immunogenic in mice, and showed no
loss of vaccine content when freeze-dried material was
stored at room temperature for 7 months (Webster et al.
2006). Further, the vaccine could be stored at 50C for 1
week without any observable loss of antigen content. Loss
was only detected when the plant material was stored at
70C for 1 week. Freeze-drying the material also resulted
in a 20-fold increase in antigen concentration, reducing the
physical amount of material required to administer each
dose. In another study by the same group, a malaria vaccine
consisting of the surface protein PyMSP4/5 from Plasmo-
dium yoelii expressed in the leaves of N. benthamiana was
found to be immunogenic in mice and stable for at least 2
years when stored at ambient temperatures (Webster et al.
2009).
Rapid production of vaccines in response
to emerging pandemics
The surge potential of PMVs
Controlling an emerging pandemic requires a swift and
aggressive response. New vaccine production systems are
needed to provide greater ﬂexibility and surge potential.
The proven ability of plant-production systems to rapidly
respond to newly emerging threats demonstrates their
potential to ﬁll this niche (D’Aoust et al. 2010). The
technology for transient expression in tobacco has been
well documented and optimised, and a number of recom-
binant proteins have been successfully produced (Tremblay
et al. 2010). Importantly for vaccine production, the species
has a high biomass, with intensive cultivation producing up
to 170 metric tonnes per hectare (Schillberg et al. 2003).
Low-alkaloid varieties can be used for oral vaccine deliv-
ery, in order to mitigate the potential effects of metabolites
(Menassa et al. 2007). The development of automated
vacuum-agroinﬁltration systems means that large numbers
of tobacco plants can now be rapidly inﬁltrated (Fischer
et al. 2004; Gleba et al. 2005) (Fig. 1). This technology
allows for bulk vaccine production within 3–10 days of the
transgene vector becoming available (Fig. 2). This is in
stark contrast with stable plant transformation systems,
which have a minimum lead-time of several months. The
ﬂexibility and speed of transient expression systems also
allows for rapid testing of different genetic constructs
without waiting for plants to be stably transformed,
selected and grown.
Current inﬂuenza vaccines
Inﬂuenzapandemicsareunpredictableeventsthathavebeen
recurring at regular intervals since at least the sixteenth
century (Ghendon 1994). There is no way to accurately
predict the probability of an inﬂuenza pandemic occurring,
and there is uncertainty regarding the type and severity of a
future pandemic strain (Smith et al. 2009). As a result, the
Fig. 1 Nicotiana benthamiana plants transiently expressing LTB
after vacuum-agroinﬁltration. Using this method, it is possible to
sustainably produce 2 g of recombinant vaccine per square metre
annually
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rapid production and delivery of a strain-speciﬁc vaccine
(WHO 2006). Currently, the majority of inﬂuenza vaccines
areproducedinfertileheneggsusingtheprevalentinﬂuenza
strains, as determined biannually by the WHO Global
Inﬂuenza Surveillance Network (Barr et al. 2010). The eggs
areinfectedwitharecombinantversionofthevirus,whichis
allowed to grow in the egg before being extracted, puriﬁed,
and treated to separate the egg proteins from the viral
particles. Approximately one to two eggs are required per
pandemic vaccine dose (Neuzil and Bright 2009).
While the egg-based production method is well estab-
lished and cost-effective, there are disadvantages. It is a
relatively lengthy process (5–6 months from the determi-
nation of vaccine strains to vaccine release), resulting in a
signiﬁcant lag time between the beginning of a pandemic
and the release of a viable vaccine in large numbers (Gerdil
2003) (Fig. 2). Egg-based production of the H1N1 vaccine
in 2009 was hindered by low yields, with production being
only half of what was originally predicted (Singh et al.
2010; Zoler 2009). Fortunately, issues regarding seasonal
availability of eggs have been somewhat overcome due to
recent funding initiatives targeting year-round egg supplies
in developed and developing countries (Partridge et al.
2010). However, unexpected poor yield can create a bot-
tleneck in vaccine production for pandemic preparedness.
Furthermore, the supply of fertile eggs can be at risk from
the spread of avian inﬂuenza (Webby and Webster 2003),
and long lead-times for vaccine development and produc-
tion means that a midcourse change in the vaccine pro-
duced is not feasible. This is of particular importance to
pandemic inﬂuenza preparedness, as potential supply is
expected to fall short of global needs by several billion
doses (Kieny et al. 2006).Under pandemic conditions it has
been predicted that few vaccine doses will be available for
populations outside of the manufacturing countries (Fedson
and Dunnill 2007). The superior ﬁnancial resources of
developed nations are likely to ensure ﬁrst access to
inﬂuenza vaccine capacity in the event of a pandemic
outbreak (PATH and Oliver Wyman 2007) leading to the
estimate that developing countries will account for 96% of
deaths resulting from a pandemic inﬂuenza outbreak
(Murray et al. 2006).
PMVs for inﬂuenza
Seasonal inﬂuenza epidemics result in three to ﬁve million
cases of severe illness worldwide each year, and up to
500,000 deaths (Carrat and Flahault 2007). Vaccines can-
not be stored from one inﬂuenza season to the next, as
strains change from year to year. This stands in marked
contrast to vaccines against infectious diseases, that do not
exhibit strain variation, as these can be mass-produced and
stock-piled in preparation. In order to protect at-risk groups
during inﬂuenza season, it is important that seasonal vac-
cine production is not compromised to focus exclusively on
pandemic production. A new rapid, ﬂexible production
system is required to adequately protect against both sea-
sonal and epidemic inﬂuenza outbreaks. The ability of
plants to act as quick response systems was recently proven
by D’Aoust and colleagues at Medicago (D’Aoust et al.
2008, 2010). Agrobacterium-mediated, transient expression
of haemagglutinin (HA) from multiple strains of inﬂuenza
was performed in N. benthamiana (D’Aoust et al. 2008).
The transiently expressing plants produced large amounts
of HA (50 mg/kg) from H5N1 (avian inﬂuenza virus) and
H1N1 (human) strains. HA was shown to assemble as
virus-like particles (VLPs), highly organised non-infectious
particles formed through the self-assembly of viral struc-
tural proteins. VLPs physically mimic live viruses and have
been demonstrated to induce robust humoral and cellular
immune responses (Grgacic and Anderson 2006). The
highlight of this research was that the puriﬁed vaccine was
produced within 3 weeks of the release of viral sequence.
Animal studies conﬁrmed the efﬁcacy and safety of this
vaccine. Mice immunised intramuscularly with two doses
of 0.5 lg of the puriﬁed H5-VLPs were protected against
H5N1 inﬂuenza virus challenge (D’Aoust et al. 2008). The
rapid nature of this platform enables plant-based produc-
tion facilities to be normally used for other recombinant
protein products, and if a pandemic emerged, the plant
facility could rapidly design an appropriate vaccine and
switch manufacture.
Cost of facilities
The cost of building a Good Manufacturing Practice
(GMP)-compliant facility that could produce 100 kg of
Fig. 2 Comparison of plant-made (D’Aoust et al. 2010) and egg-
based (WHO 2009) inﬂuenza vaccine production timelines. Transient
plant-based production can potentially reduce the time from target
identiﬁcation to vaccine release by over one third. Day 0: Target
strain identiﬁed. A Pre-production, (cloning and transformation of
Agrobacterium for plants, preparation of vaccine strain for egg-based
system). B Production time for ﬁrst batch. C Estimated 2.5 months for
testing and regulatory approval
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0.1 mg doses), has been estimated to be under 15 million
USD, and after this initial outlay upkeep costs are minimal
(Gleba et al. 2005).The plant-production system is a more
affordable option than many current vaccine production
systems that routinely cost in the hundreds of millions of
dollars to start and maintain. Further, the plant-based sys-
tem can produce number of vaccine doses unable to be
matched by current facilities. In comparison to the plant-
made, one billion doses for 15 million USD, Sanoﬁ Pasteur
is a traditional vaccine production facility in Pennsylvania,
USA that can produce 100 million inﬂuenza vaccine doses
per year at a cost of 150 million USD (Sanoﬁ Pasteur
2009). Even more costly is Novartis’ new cell culture
facility in North Carolina, USA. This new facility will cost
almost one billion USD in investments with an expected
300 million doses of vaccine produced per year (Novartis
2009).
PMVs in developing countries
Orphan diseases
The distribution of disease burden is not uniform
throughout the world. Much of the impact is felt dispro-
portionally in developing countries, where health care and
sanitation programs are limited. There are also diseases
that are geographically restricted, such as the parasitic
Chagas disease whose 10–12 million sufferers are almost
all from Central and South America, and Onchocerciases,
of which 99% of an estimated 18 million cases occur in
sub-Saharan Africa (Hotez and Ferris 2006). Due to the
poor potential market for vaccines for these diseases,
manufacturers often overlook them, and for this reason
they earn the name of orphan diseases (Trouiller et al.
2002). However, for the countries affected, orphan dis-
eases can actually offer the greatest return on investments
in disease control (Boutayeb 2010). It is therefore of great
beneﬁt for countries to be able to cheaply and easily
produce vaccines tailored to the local conditions and
strains, as well as easily distribute them to remote
regions. Providing proper regulatory oversight exists to
ensure that GMP is established and maintained, PMVs
can be produced cheaply and locally on small scales using
basic technology. As well as immediate effects such as
easing the strain on health services caused by preventable
disease, constant local production could allow countries to
initiate eradication programs through maintainable vacci-
nation schedules. This would be particularly effective
against diseases that present stable vaccine targets with
low mutation rates.
Hidden costs of traditional vaccines
The aforementioned cost of the cold-chain greatly strains
the resources of developing nations. In addition, injected
vaccines carry the cost of needles and safe disposal meth-
ods, and require trained staff for administration. While the
purchase cost of the syringe is in itself low, there is an
associated risk of iatrogenic disease (Giudice and Campbell
2006). When the societal cost of spread of blood-borne
pathogens (for example, HIV and hepatitis B) through the
reuse or inappropriate disposal of needles is included into
the analysis, the cost of needle delivery through standard
disposable syringes escalates from 0.10 to 25.29 USD
per delivery (Ekwueme et al. 2002). Auto-disabling (AD)
needles are now the most common delivery system and
have a total cost of only 0.91 USD, although the cost of the
device is originally more expensive at 0.14 USD each
(Ekwueme et al. 2002). The main reason for this usage shift
is the donation of AD needles by GAVI, WHO, UNICEF
and other agencies. As low-middle income countries are not
eligible for assistance, they still have low AD use (Levin
et al. 2010), which correlates strongly to the incidence of
HIV (Deuchert and Brody 2007). In contrast, oral delivery
of PMVs can sidestep these problems. Besides being highly
stable, the fact that plants are a regular part of the human
diet means that only minimal down-stream processing of
material is necessary. It is hypothesised that the plant cell
wall protects the antigen from digestion before it is taken up
to induce an immune response (Sala et al. 2003). It must be
stressed, however, that much research is yet required to
reduce the variability of immune responses, and to ensure
the safety of PMVs for oral vaccination.
Regulatory hurdles
There are regulatory issues for PMVs to overcome beyond
the approval process, as there is the risk that seeds or pollen
from stably transformed plants could escape containment
and become included within food crops or the wild popu-
lation. This leads to concerns regarding oral tolerance
of the vaccine (Kirk et al. 2005; Ling et al. 2010). Oral
tolerance is a form of peripheral tolerance through which
external agents such as dietary proteins and commensal
bacteria that gain access to the body through a natural route
are recognised as non-harmful and do not induce poten-
tially harmful local or systemic immune responses (Faria
and Weiner 2005). Oral tolerance can occur if the antigen
is administered too frequently, or at too high or too low a
dose (Gregerson et al. 1993). It is not yet widely under-
stood, although it is proposed that it could be counteracted
by high levels of antigen accumulation in the plant, as this
will reduce the level of tolerance induced by the plant
794 Plant Cell Rep (2011) 30:789–798
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Potential oral PMVs will need to be assessed on a case-by-
case basis to ensure that the antigen formulation, dose size,
and immunisation protocols strike a balance between
immune response and oral tolerance. It is also almost
certain that any plants grown to produce vaccines will have
to be done under GMP in physically enclosed greenhouses.
While there are several molecular methods for gene con-
tainment, such as terminator genes or plastid engineering,
none of these can achieve 100% containment (Murphy
2007), which over a period of time can represent a sig-
niﬁcance likelihood of escape (Lee and Natesan 2006).
Local production of PMVs
There is an important niche that can be ﬁlled by low-cost
PMVs, and the technology is advancing to the point where it
can meet the requirements to be successfully employed.
Whiletransientexpressionoftenyieldshigherantigenlevels
than stably transformed plants (Daniell et al. 2009), the
additional puriﬁcation and production costs required would
likely be beyond what many poorer regions can feasibly
spend. The advantages of being able to grow stably trans-
formed plants with local technology, and to orally vaccinate
using minimally puriﬁed plant-made material makes trans-
genic plants a desirable system for developing countries.
After the plants have been grown and contained in
greenhouses, the path from raw biomass to oral vaccine is
relatively straightforward. The plant material is harvested
and freeze-dried, although this step can be potentially
replaced by air-drying in some cases (Zhang et al. 2006).
The dried material is then powdered to form batches, and
samples can be taken to analyse antigen content and detect
any potential toxins. While this step may require more
specialised equipment and training, it can easily be
undertaken offsite, with samples being sent to universities
or biotechnology companies. Once the dosage has been
determined, the required amount of plant material can be
delivered under supervision as a paste, capsule or suspen-
sion (Hefferon 2010).
The cost of vaccine production in tomatoes has been
estimated by Kirk and Webb (2005) for a one-hectare
greenhouse. Assuming a required dose of 1 mg of vaccine,
and expression levels of 20 and 40 lg/g fresh weight, the
cost to grow and freeze-dry a vaccine batch works out at
22.8 and 11.4 US cents per dose, respectively. If the level
of expression can be increased, or the required dose
decreased, it is possible to reduce the cost per dose to
below 1 cent. Producing 10–20 million doses of vaccine in
this way has been estimated to cost between 1.8 and 2.5
million USD per year. It must be noted that these estimates
are highly simpliﬁed, and exclude many additional costs,
such as packaging, labour, maintenance and supplies. The
high cost of freeze-dryers is a major limiting factor, and
highlights the need to increase expression levels and
explore other avenues such as air-drying for preservation.
In reality, this high volume of material and vaccines is
unlikely to be feasible for many developing regions where
they would be of use. If smaller greenhouses were used, for
example 100 m
2, the associated costs would be greatly
reduced, especially those associated with freeze-driers, as
freeze-driers at this scale cost approximately 30,000 USD.
The cost to build a greenhouse of this size is approximately
108,000 USD, assuming a cost of 100 USD per square foot
(Kirk and Webb 2005). The lower volume also make
handling a lot easier, as only about 100 kg of fruit would
need to be processed per week, which when freeze-dried
reduces to about 5 kg. This amount of plant material can
easily be ground in a bench top blender and mixed in large
containers. From this mix, multiple samples can be taken
for analysis of vaccine and contaminant content. The
vaccine batch can then be formed into tablets or capsules,
and distributed as needed. This method can produce around
104,000 doses per year at a cost of around 138,000 USD for
the greenhouse and freeze dryer, resulting in a vaccine cost
of 8.8 cents per dose over 15 years. As above, this estimate
does not take into account other associated costs, although
if yearly running costs are estimated at 10,000 USD the
price per dose over 15 years increases to 18.5 cents. These
expenses would likely be offset through the eliminated
need for needles (thus saving on purchase, disposal, and the
cost of trained staff) and cold storage (especially if the
vaccine is transported between villages).
Additional beneﬁts of PMVs
Localised production facilitates easier and cheaper distri-
bution of vaccines doses, increasing overall coverage rates.
As well as the direct effect of reducing disease burdens,
vaccines produced in this way can also present broader-
reaching beneﬁts, such as increasing herd immunity. This
can result in a signiﬁcant increase in the reported health
beneﬁts of a vaccine (Jeuland et al. 2010; Lloyd et al. 2008).
For example, it is estimated that 80–86% coverage of
immunity would be sufﬁcient to eliminate mumps, polio,
rubella and smallpox from a population (Smith 2010). Herd
immunity reduces the spread of disease between unvacci-
nated people, and also provides an extra degree of protec-
tion to those who have been vaccinated but had weaker
immune responses. As it is quite common for the efﬁcacy of
vaccines to be much lower in developing regions, possibly
due to reduced overall health or differences in strains
(Madhi et al. 2010), an increase in herd immunity can
provide a signiﬁcant beneﬁt. This will be most pronounced
in areas where people live in close proximity to each other
(Ali et al. 2005), as is often the case in developing countries.
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Research over the past 20 years has proven that plants are a
ﬂexible vaccine production system capable of expressing a
broad range of different protective antigens that can be
puriﬁed and delivered by injection and with evidence of
feasibility of oral delivery. However, reaching the full
potential of PMVs relies on effective delivery systems.
While the most advanced PMVs are puriﬁed and only use
plants as a production system, oral administration is con-
sidered the easiest means of delivery. The ease of admin-
istration can result in increased patient compliance and is
highly compatible with immunisation schemes in devel-
oping nations. Before oral delivery of PMVs can become a
reality, critical safety and regulatory issues concerning
genetically modiﬁed organisms and pharmaceuticals will
need to be addressed, most likely on a case-by-case basis.
While pessimism regarding the ability for the technol-
ogy to be accepted and implemented by regulatory bodies
remains, the accomplishments of PMVs should not be
undervalued. Many of the hypothesised advantages have
been realised, and many initial claims have been justiﬁed.
PMVs have been produced and puriﬁed to a deliverable
product in a timeframe suitable for responding to pan-
demics, where existing technologies fall short. Minimally
processed plant material has been shown to be stable
without the addition of any preservatives at time intervals
and temperatures beyond the reach of current vaccines.
This can facilitate vaccination in remote regions without
the need for signiﬁcant investment in infrastructure, as well
as the stockpiling of vaccines in regions that are prone to
disease outbreaks. Finally, the use of PMVs would allow
governments to address speciﬁc problems such as orphan
diseases and reduce their dependence on developed nations
for vaccine supplies. Investigations now need to concen-
trate on improved delivery methods, speciﬁcally via
mucosal routes, to enable the technology to reach its full
potential and aid the areas of the world afﬂicted the most.
PMVs are potentially powerful tools in the ﬁght against
disease, and if properly implemented could play a signiﬁ-
cant role in increasing global health, both in the scope of
the 2015 Millennium Development Goals and beyond.
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